Lipella Pharmaceuticals Inc. (LIPO) Cash Flow Statement
Where LIPO’s cash came from and went, 2024
December 31, 2024 · U.S. dollars- Cash from operations
- −$4.0M
- Capital expenditures
- $3 0.0% of revenue
- Free cash flow
- −$4.0M −736.6% margin
- Returned to shareholders
- —
- Change in cash
- −$1.1M cash at year-end $2.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
LIPO operating cash flow, capex and free cash flow
LIPO cash flow trends, 2019–2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$39,1172019 | −$4.0M2024 | — | |
| Capital expenditures | $02019 | $32024 | — | |
| Free cash flow | −$39,1172019 | −$4.0M2024 | — | |
| Free cash flow margin | −5.6%2019 | −736.6%2024 | −731.0 pts | |
| Stock-based compensation | $57,7142020 | $749,3962024 | +89.8%/yr | |
| Capex / revenue | 0.0%2019 | 0.0%2024 | 0.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
LIPO cash flow by activity
LIPO net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
LIPO cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$5.0M | −$4.6M | −$2.6M | −$1.9M | −$61,656 | −$61,848 |
| Depreciation & amortization | $2,886 | $1,685 | $0 | — | — | $53,791 |
| Stock-based compensation | $749,396 | $1.4M | $747,396 | $728,799 | $57,714 | — |
| Change in working capital | $113,235 | −$9,108 | $9,523 | $197,609 | −$32,280 | $14,340 |
| Other non-cash items | $200,000 | $121,200 | $9,612 | −$50,206 | $7,645 | −$45,400 |
| Cash from operating activities | −$4.0M | −$3.2M | −$1.8M | −$989,271 | −$28,577 | −$39,117 |
| Investing activities | ||||||
| Capital expenditures | −$3 | −$14,434 | $0 | $0 | $0 | $0 |
| Investments (net) | $0 | −$14,434 | $300,546 | −$300,546 | −$300,546 | −$300,546 |
| Acquisitions & other investing | — | $14,434 | $0 | $0 | $0 | $0 |
| Cash from investing activities | — | −$14,434 | $300,546 | −$300,546 | −$300,546 | −$300,546 |
| Financing activities | ||||||
| Net borrowing (repayment) | $0 | −$275,000 | $275,000 | $275,000 | $57,040 | $25,000 |
| Shares issued | $2.8M | $1.6M | $5.0M | $2.1M | $552,268 | $0 |
| Other financing | $0 | $0 | $0 | −$275,000 | $0 | $0 |
| Cash from financing activities | $2.8M | $1.3M | $5.2M | $2.1M | $609,308 | $25,000 |
| Summary | ||||||
| Net change in cash | −$1.1M | −$1.8M | $3.7M | $807,092 | $580,731 | −$14,117 |
| Cash at end of period | $2.2M | $3.3M | $5.1M | $1.4M | $606,736 | $26,005 |
| Free cash flow | −$4.0M | −$3.2M | −$1.8M | −$989,271 | −$28,577 | −$39,117 |
| Free cash flow margin | −736.6% | −703.8% | −994.4% | −381.4% | −3.0% | −5.6% |
| Capex / revenue | 0.0% | 3.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$3.89B | −$1.3M | −$1.3M | −$1.4M | −$1.4M | −$938,146 | −$1.2M | −$688,884 | −$1.3M | −$1.5M | −$1.1M | −$363,925 |
| Depreciation & amortization | $722 | $721 | $722 | $721 | $722 | $1,371 | $72 | $723 | $962 | $0 | — | — |
| Stock-based compensation | $0 | $0 | $0 | $80,666 | $379,425 | $80,665 | $208,640 | −$1.4M | $298,759 | $847,618 | $208,639 | $0 |
| Change in working capital | $226,697 | −$106,372 | −$120,325 | $369,869 | $411,390 | −$62,033 | −$605,991 | −$39,549 | $213,286 | $41,353 | −$224,198 | $129,663 |
| Other non-cash items | $1.53B | −$1 | $0 | $3 | −$3 | −$649 | $200,649 | $1.4M | $121,200 | −$5,394 | $5,394 | $2,703 |
| Cash from operating activities | −$2.36B | −$1.4M | −$1.4M | −$990,413 | −$653,103 | −$918,792 | −$1.4M | −$727,710 | −$689,363 | −$655,109 | −$1.1M | −$231,559 |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$14.4M | −$14,434 | $0 | $0 | $0 |
| Investments (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$14,434 | $0 | $0 | $0 |
| Acquisitions & other investing | — | — | — | — | — | — | — | $0 | $14,434 | — | — | $300.2M |
| Cash from investing activities | — | — | — | — | — | — | — | −$14.4M | −$14,434 | — | — | $300.2M |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | — | $0 | $0 | — | — | — | — | — | — | $275,000 |
| Shares issued | $0 | $0 | $3.5M | $1.8M | $820,332 | $0 | $200,000 | $0 | $0 | $0 | $0 | $5.0M |
| Other financing | $4.21B | −$10,047 | $0 | $0 | $0 | $0 | $0 | $1.6M | −$2,281 | −$250,000 | −$25,000 | $0 |
| Cash from financing activities | $4.21B | −$10,047 | $3.5M | $1.8M | $820,332 | $0 | $200,000 | $1.6M | −$2,281 | −$250,000 | −$25,000 | $5.2M |
| Summary | ||||||||||||
| Net change in cash | $1.85B | −$1.4M | $2.0M | $831,129 | $167,229 | −$918,794 | −$1.2M | $883,891 | −$703,797 | −$905,109 | −$1.1M | $5.0M |
| Cash at end of period | $1.86B | $2.8M | $4.2M | $2.2M | $1.4M | $1.2M | $2.1M | $3.3M | $2.4M | $3.1M | $4.0M | $5.1M |
| Free cash flow | −$2.36B | −$1.4M | −$1.4M | −$990,413 | −$653,103 | −$918,792 | −$1.4M | −$727,710 | −$703,796 | −$655,109 | −$1.1M | −$231,559 |
| Free cash flow margin | — | −1.7% | −1.1% | −570.3% | −812.5% | −673.4% | −951.8% | −161.9% | −676.4% | −614.1% | −913.2% | −153.3% |
| Capex / revenue | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3,207.1% | 13.9% | 0.0% | 0.0% | 0.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
LIPO cash generation
In fiscal 2024 (ended December 31, 2024), Lipella Pharmaceuticals generated -$4.0 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$4.0 million, −736.6% of revenue. Cash and equivalents fell by $1.1 million over the year.
Related: LIPO income statement, LIPO balance sheet. See the LIPO stock overview for the latest quote and news.
LIPO cash flow FAQ
What is Lipella Pharmaceuticals's free cash flow?
Lipella Pharmaceuticals's free cash flow was -$4.0 million in fiscal 2024: -$4.0 million of operating cash flow minus $0.0 million of capital expenditures It was -$3.2 million a year earlier..
How much cash does Lipella Pharmaceuticals generate from operations?
Lipella Pharmaceuticals generated -$4.0 million of cash from operating activities in fiscal 2024.
How much does Lipella Pharmaceuticals spend on capital expenditures?
Lipella Pharmaceuticals spent $0.0 million on capital expenditures in fiscal 2024, 0.0% of revenue, compared with $0.0 million the year before.